Yan Jin, Jin Ting, Wang Li
School of Medicine, Jianghan University, Wuhan 430056, Hubei Province, China.
Department of Hematology, The Central Hospital of Wuhan, Wuhan 430014, Hubei Province, China.
World J Clin Cases. 2023 Oct 16;11(29):7200-7206. doi: 10.12998/wjcc.v11.i29.7200.
Immunosuppressive therapy and matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT) are the preferred treatments for aplastic anemia (AA).
In this report, we describe a 43-year-old male patient with severe AA who carried (also known as ), , and mutations. Screening of the family pedigree revealed the same mutation in his mother and older brother, with his older brother also carrying the variant and demonstrating normal telomere length and hematopoietic function. The patient was successfully treated with oral cyclosporine A, eltrombopag, and acetylcysteine, achieving remission 4 years after receiving MSD-HSCT from his older brother.
This case provides a valuable clinical reference for individuals with suspected pathogenic gene mutations, normal telomere length, and hematopoietic function, highlighting them as potential donors for patients with AA.
免疫抑制治疗和匹配的同胞供体造血干细胞移植(MSD-HSCT)是再生障碍性贫血(AA)的首选治疗方法。
在本报告中,我们描述了一名43岁的重度AA男性患者,他携带(也称为)、和突变。对家族谱系的筛查显示,他的母亲和哥哥存在相同的突变,他的哥哥还携带变体,且端粒长度和造血功能正常。该患者通过口服环孢素A、艾曲泊帕和乙酰半胱氨酸成功治疗,在接受来自其哥哥的MSD-HSCT 4年后实现缓解。
该病例为疑似致病基因突变、端粒长度正常和造血功能正常的个体提供了有价值的临床参考,突出了他们作为AA患者潜在供体的可能性。